Clinical Validation of a Unani Pharmacopoeial Formulation â?? Raughan Ikseer for symptomatic relief in Wajaâ?? al-AsnÄ?n (Toothache)

Central Council for Research in Unani Medicine0 个研究点目标入组 384 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Patients of either sex in the age group 18-65 years.
•Patients having Wajaâ?? al-AsnÄ?n (Toothache) with or without any of the following symptoms:
•ï?§Waram al-Lisa (Gingival swelling)
•ï?§Humra al-Lisa (Gingival erythema)
•ï?§Nazf al-Lisa (Gingival bleeding)
•ï?§HassÄ?siyat HarÄ?riyya (Thermal sensitivity) â?? Pain triggered by Cold or Heat
•ï?§SudÄ?â?? (Headache)

•Toothache does not respond to standard therapy.
•Toothache accompanied by impaired neurological functions (loss of balance, weakness, numbness, or speech disturbances), double vision, seizures, mental disturbances, and loss of consciousness.
•Toothache accompanied by persistent nausea, vomiting, fever and stiff neck.
•Presence of a periodontal abscess as diagnosed from clinical examination of the painful tooth.
•Presence of concomitant oral pain due to any other condition such as soft-tissue lesions (e.g., aphthous/ traumatic ulcer, herpes labialis, acute necrotizing ulcerative gingivitis) or multiple hard-tissue (e.g., carious) lesions; pain due to other surgical procedures, injuries or dental surface sensitivity.
•Known cases of any other acute illness.
•Known cases of severe Renal/ Hepatic/ Cardiac ailments.
•Pregnant and lactating women.
•History of Hypersensitivity to the study drug or any of its ingredients.
•History of addiction (alcohol, drugs)

发起方